Pricing Log in Create free account

Halozyme Therapeutics, Inc. (HALO) vs Kymera Therapeutics, Inc. (KYMR)

Halozyme Therapeutics, Inc. and Kymera Therapeutics, Inc. are both Biotechnology companies. Halozyme Therapeutics, Inc. is the larger, with a market value of $14.0B against $10.9B — 1.3× the size. Kymera Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Halozyme Therapeutics, Inc. trades at 29.5×. Kymera Therapeutics, Inc. grew revenue faster over the last twelve months: 134.8% against 45.0%. Halozyme Therapeutics, Inc. has the higher net margin (26.9% vs 0.00%) and the higher return on invested capital (19.9% vs −39.3%). Across the 18 metrics below, Halozyme Therapeutics, Inc. leads on 13 and Kymera Therapeutics, Inc. on 5.

Valuation

Metric HALO KYMR Biotechnology median
P/E 29.50 n/m 10.26
P/S 7.82 119.82 9.18
P/B n/m 7.79 2.05
Price to free cash flow 15.91 n/m 24.81
EV/EBITDA 22.63 n/m 0.65
EV/Sales 9.03 110.58 8.98
Earnings yield 3.39% (2.88%) (34.89%)
Free cash flow yield 6.28% (2.30%) (24.52%)

Profitability

Metric HALO KYMR Biotechnology median
Gross margin 82.27% 100.00% 65.16%
Operating margin 37.41% 0.00% 0.00%
Net margin 26.93% 0.00% 0.00%
Free cash flow margin 49.84% 0.00% 0.00%
Return on equity 216.38% (27.29%) (50.12%)
Return on assets 17.05% (24.36%) (45.60%)
Return on invested capital 19.87% (39.30%) 0.00%

Growth

Metric HALO KYMR Biotechnology median
Revenue growth (TTM) 45.03% 134.84% 6.26%
EPS growth (last fiscal year) (25.36%) (23.83%) 29.88%
Revenue growth, 5-year CAGR 39.16% 2.87% 9.75%
Net income growth, 5-year CAGR 19.68% 0.00% 0.00%

Health

Metric HALO KYMR Biotechnology median
Debt to equity (58.84) 0.00 0.00
Current ratio 3.88 11.13 4.89
Net debt to EBITDA 3.56 2.42 1.01

Dividend

Metric HALO KYMR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric HALO KYMR Biotechnology median
Market cap 13.96b 10.94b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack